S&P 5007,736.52▲1.8% Nasdaq26,584.99▲2.6% Dow54,085.88▲1.7% Russell 2K3,036.98▲1.9% 10-Yr4.63%−6bp VIX16.50+0.64 WTI$75.32▼6.2% Gold$4,133.60▲2.5% EUR/USD1.153▼0.1% BTC$64,170▲0.2% Nikkei63,755▼0.9%
At close · Tue, Aug 4, 2026
Daily Market Updates.

Earnings

Home›Earnings›Results›Eli Lilly revenue jumps 48% as demand for GLP-1 drugs…

Eli Lilly revenue jumps 48% as demand for GLP-1 drugs rises

Lilly said sales growth was fueled by higher-than-expected demand for Mounjaro and Zepbound.

Reported · Written up by our desk · Results

Eli Lilly reported revenue growth of 48%, citing stronger demand for its GLP-1 therapies, Mounjaro and Zepbound, MarketWatch reported.

The drugs are used for Type 2 diabetes and weight loss, and the outlet said sales outperformance reflected demand that came in higher than expected.

The update highlights how Eli Lilly’s GLP-1 product demand continues to drive company performance.

← Newer storyIncome needed to afford a typical US home stays near record high

More like this

EarningsDisney beats earnings estimates as parks and streaming gain traction
EarningsCaterpillar posts record quarter and raises guidance on datacenter demand
EarningsDisney stock jumps after surprisingly strong earnings
EarningsNavin Fluorine profit more than doubles in June quarter
EarningsCVS tops estimates and raises guidance as insurance unit improves

Sources

MarketWatchLilly’s revenue soars 48%, driven by demand for its GLP-1s
MarketWatchLilly’s revenue soars 48%, driven by demand for its GLP-1s

Get the close, explained.

One email every trading day: what moved, why it moved, and what's on deck tomorrow. Read in 3 minutes.

Free. Unsubscribe anytime.